Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) EPS (Basic): 2013-2025

Historic EPS (Basic) for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to -$3.69.

  • KalVista Pharmaceuticals' EPS (Basic) rose 14.95% to -$0.91 in Q2 2025 from the same period last year, while for Apr 2025 it was -$3.69, marking a year-over-year decrease of 31.79%. This contributed to the annual value of -$3.69 for FY2025, which is 7.27% down from last year.
  • As of FY2025, KalVista Pharmaceuticals' EPS (Basic) stood at -$3.69, which was down 7.27% from -$3.44 recorded in FY2024.
  • In the past 5 years, KalVista Pharmaceuticals' EPS (Basic) registered a high of -$2.42 during FY2021, and its lowest value of -$3.69 during FY2025.
  • In the last 3 years, KalVista Pharmaceuticals' EPS (Basic) had a median value of -$3.44 in 2024 and averaged -$3.49.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' EPS (Basic) slumped by 47.56% in 2021, and later rose by 0.89% in 2023.
  • KalVista Pharmaceuticals' EPS (Basic) (Yearly) stood at -$2.42 in 2021, then plummeted by 38.84% to -$3.36 in 2022, then grew by 0.89% to -$3.33 in 2023, then fell by 3.30% to -$3.44 in 2024, then fell by 7.27% to -$3.69 in 2025.